An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...

We can laugh about it now. See the funny side. The sunny-side-up. But that is only because Benn-Eubank III has scrambled everybody’s minds, memories and ability to think.